Using prostate cancer cell lines and GEM models, several studies reported that CHD1 loss causes defects in HR-mediated DNA damage repair (DDR) and increases sensitivity to DNA-damaging therapies (21, 24, 88, 89). The gene discussed is CHD1; the disease is prostate cancer.